Great trading yesterday in Day 1 in the $5K Challenge. Kyle’s account is up 10% and he will be looking to continue that trend today.
Remember, the big holiday 70% off sale ends this Thursday at midnight. So now is the time to act!
Biotechs pulled back yesterday, so Kyle will be watching for the next consolidation period to start slowly adding into some new names.
Below you will note two new names on the watch list.
Just a reminder, charts and targets are updated every Monday morning!
New Catalyst Swing names (1 – 4 week holds) Kyle’s watching…
Arca Biosciences (ABIO)
Catalyst Dates: Phase 2b data due in March
Buy Zone: $1.60 to $1.80
Profit Zone: 2.20 or higher
Stop Zone: $1.40 or below
Aveo Pharmaceuticals (AVEO)
Catalyst Dates: Phase 2 Cancer data due out Feb 8-10
Buy Zone: $2.60 to $2.80
Profit Zone: 3.30 or higher
Stop Zone: $2.50 or below
Catalyst Swing names (1 – 4 week holds) I am watching…
Flex Pharma (FLKS)
Catalyst Dates: Phase 2 Multiple Sclerosis data due out in late 1Q
Buy Zone: $3.60 to $3.80
Profit Zone: 5.00 or higher
Stop Zone: $3.00 or below
Otonomy (OTIC)
Catalyst Dates: FDA approval date of March 2, 2018.
Buy Zone: $5.50 to $5.75
Profit Zone: $7.50 or higher
Stop Zone: $5.00 or below
Nabriva Therapeutics (NBRV)
Catalyst Dates: Phase 3 antibiotic data due out “spring 2018”
Buy Zone: $6.00 to $6.40
Profit Zone: $8.00 or higher
Stop Zone: $5.50 or below
Asterias Biotherapeutics (AST)
Catalyst Dates: Phase 1/2 cohort data due in February
Buy Zone: $2.15 to $2.30
Profit Zone: 2.95 or higher
Stop Zone: $2.00 or below
Cidara Therapeutics (CDTX)
Catalyst Dates: Phase 2 Candidemia data due in the 1Q (likely sometime in mid February)
Buy Zone: $6.60 to $7.20
Profit Zone: $9.00 or higher
Stop Zone: $6.40 or below
Sophiris Bio (SPHS)
Catalyst Dates: Phase 2b initial biopsy data due late First Quarter.
Buy Zone: $2.15 to $2.30
Profit Zone: $2.80 or higher
Stop Zone: $1.95 or below
Apricus Bioscience (APRI)
Catalyst Dates: FDA approval date of February 17th.
Buy Zone: $1.90 to $2.10
Profit Zone: $2.80 or higher
Stop Zone: $1.75 or below
Antares Pharma (ATRS)
Catalyst Dates: FDA approval date for preterm birth injector on February 14
Buy Zone: $2.00 to $2.20
Profit Zone: $2.80 or higher
Stop Zone: $1.80 or below
Kempharm (KMPH)
Catalyst Dates: FDA approval date of February 23 for Acute Pain
Buy Zone: $4.25 to $4.50
Profit Zone: $5.50 or higher
Stop Zone: $4.00 or below
Synergy Pharmaceuticals (SGYP)
Catalyst Dates: FDA approval date of January 24th, 2018
Buy Zone: $2.00 to $2.20
Profit Zone: $3.00 or higher
Stop Zone: $1.75 or below
BioLine Rx (BLRX)
Catalyst Dates: Phase 2a partial results due out January 18-20 at the ASCO Gastrointestinal Cancers event.
Buy Zone: $1.00 to $1.10
Profit Zone: $1.30 or higher
Stop Zone: $.90 or below
